- Date: March 13, 2018
It is the fifth spin-off that has resulted from the CaixaImpulse programme, in this case from the Kit for early Alzheimer's detection project from 2015, led by Marta Barrachina. Barrachina is the general director of the new company, and is joined by Ramón Reñé and Jordi Gascón as medical advisory board.
The in vitro diagnostic test developed by ADmit Therapeutics determines whether certain mitochondrial biomarkers are present in the blood. These biomarkers can indicate signs of the disease before the brain starts producing the protein aggregates that characterise Alzheimer's. Early diagnosis would allow those affected to start receiving the treatments available to slow down the progress of the disease, as there are still no treatments to reverse it. The company is seeking private investors as a step towards CE certification.
More programme highlights
September 12, 2018
On 6 September, CaixaForum Barcelona hosted a Pitch Day for the projects that took part in the CaixaImpulse 2017.
September 07, 2018
A diagnostic kit for septicaemia and a medical device to reduce hospital-acquired infections are some examples of the projects featured in the 2018 programme.
August 30, 2018
From 3-7 September, CaixaImpulse will host the first of four weeks of training available to this year’s participants.